94 related articles for article (PubMed ID: 22882485)
41. Targeting inhibitor of apoptosis proteins for cancer therapy: a double-edge sword?
Fulda S
J Clin Oncol; 2014 Oct; 32(28):3190-1. PubMed ID: 25113757
[No Abstract] [Full Text] [Related]
42. Thioproline and reversal of cancer.
Gosálvez M
Lancet; 1983 May; 1(8333):1108. PubMed ID: 6133140
[No Abstract] [Full Text] [Related]
43. Cytostatic treatment in veterinary medicine.
Rutteman GR; Teske E
Vet Q; 1995 Apr; 17 Suppl 1():S25-7. PubMed ID: 7571297
[No Abstract] [Full Text] [Related]
44. Introduction to the Biochemical Pharmacology special issue on targeted cancer therapy.
Smalley KS
Biochem Pharmacol; 2010 Sep; 80(5):549. PubMed ID: 20211148
[No Abstract] [Full Text] [Related]
45. Comparison between Ki-67 index and mitotic index for predicting outcome in canine mast cell tumours.
van Lelyveld S; Warland J; Miller R; Maw H; Foale R; Goodfellow M; Dobson J
J Small Anim Pract; 2015 May; 56(5):312-9. PubMed ID: 25728289
[TBL] [Abstract][Full Text] [Related]
46. Case report: Adjuvant therapy with toceranib for an incompletely resected renal cell carcinoma with suspected pulmonary metastasis in a dog.
Lee DE; Nam CH; Yoon HY; Bae K; Yoon KA; Kim JH
Front Vet Sci; 2023; 10():1287185. PubMed ID: 38026615
[TBL] [Abstract][Full Text] [Related]
47. A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions.
Žagar Ž; Schmidt JM
Animals (Basel); 2023 Sep; 13(19):. PubMed ID: 37835664
[TBL] [Abstract][Full Text] [Related]
48. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.
Candido MF; Medeiros M; Veronez LC; Bastos D; Oliveira KL; Pezuk JA; Valera ET; Brassesco MS
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839989
[TBL] [Abstract][Full Text] [Related]
49. Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines.
Ustun-Alkan F; Bakırel T; Üstüner O; Anlas C; Cinar S; Yıldırım F; Gürel A
J Vet Res; 2021 Sep; 65(3):351-359. PubMed ID: 34917849
[TBL] [Abstract][Full Text] [Related]
50. An RNA-Seq-Based Framework for Characterizing Canine Prostate Cancer and Prioritizing Clinically Relevant Biomarker Candidate Genes.
Thiemeyer H; Taher L; Schille JT; Packeiser EM; Harder LK; Hewicker-Trautwein M; Brenig B; Schütz E; Beck J; Nolte I; Murua Escobar H
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768937
[TBL] [Abstract][Full Text] [Related]
51. Expression of platelet-derived growth factor receptor-α/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.
Song JH; Yu DH; Hwang TS; Seung BJ; Sur JH; Kim YJ; Jung DI
Vet Med Sci; 2020 Nov; 6(4):965-974. PubMed ID: 32585777
[TBL] [Abstract][Full Text] [Related]
52. Canine CD117-Specific Antibodies with Diverse Binding Properties Isolated from a Phage Display Library Using Cell-Based Biopanning.
Alfaleh MA; Arora N; Yeh M; de Bakker CJ; Howard CB; Macpherson P; Allavena RE; Chen X; Harkness L; Mahler SM; Jones ML
Antibodies (Basel); 2019 Feb; 8(1):. PubMed ID: 31544821
[TBL] [Abstract][Full Text] [Related]
53. Successful management of lymphangiosarcoma in a puppy using a tyrosine kinase inhibitor.
Kim JH; Yoon H; Yoon HY; Eom K; Sung HJ; Kim JH
Can Vet J; 2018 Apr; 59(4):367-372. PubMed ID: 29606721
[TBL] [Abstract][Full Text] [Related]
54. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
[TBL] [Abstract][Full Text] [Related]
55. IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach.
Singer J; Jensen-Jarolim E
J Carcinog Mutagen; 2014 May; 5(3):1000176. PubMed ID: 25264496
[TBL] [Abstract][Full Text] [Related]
56. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.
Halsey CH; Gustafson DL; Rose BJ; Wolf-Ringwall A; Burnett RC; Duval DL; Avery AC; Thamm DH
BMC Vet Res; 2014 May; 10():105. PubMed ID: 24885200
[TBL] [Abstract][Full Text] [Related]
57. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Bavcar S; Argyle DJ
Vet Comp Oncol; 2012 Sep; 10(3):163-73. PubMed ID: 22882485
[TBL] [Abstract][Full Text] [Related]
58. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
59. Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
Di Lorenzo L
J Clin Oncol; 2007 Jul; 25(19):2858-9; author reply 2859-61. PubMed ID: 17602094
[No Abstract] [Full Text] [Related]
60. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
